GeoVax Advances Mpox Vaccine Development Amid WHO's Global Health Emergency Declaration
GeoVax Labs, Inc. is responding to the WHO's declaration of Mpox as a global public health emergency by advancing its GEO-MVA vaccine, aiming to address the urgent need for diversified vaccine supply and enhanced pandemic preparedness.
The World Health Organization's recent declaration of Mpox as a Public Health Emergency of International Concern highlights the escalating threat posed by the Clade 1 strain of the Mpox virus, now spreading beyond Central Africa to Europe, Asia, and North America. GeoVax Labs, Inc. is at the forefront of addressing this crisis with its GEO-MVA vaccine, a potential game-changer in the global fight against Mpox.
With the global vaccine supply dangerously reliant on a single manufacturer, GeoVax's GEO-MVA represents a critical alternative, promising to enhance biosecurity, affordability, and equitable distribution. The vaccine's development using an advanced continuous avian cell line manufacturing process aims to increase production yield, eliminate dependency on pathogen-free chicken eggs, and reduce costs, marking a significant step forward in vaccine technology.
GeoVax's efforts are not just about combating the current Mpox outbreak but are also a strategic move to strengthen future pandemic resilience. The company's engagement with U.S. federal agencies and its selection for award under BARDA’s Rapid Response Partnership Vehicle underscore the importance of GEO-MVA in national security and public health readiness. As the world grapples with the spread of Clade 1 Mpox, GeoVax's initiative offers hope for a more prepared and resilient global health infrastructure.